NDF Research Update from 3 May 2018 on PAB website:
http://www.patrys.com/site/analysts-reports/NDFResearchUpdate.pdf
We expect that the rest of 2018 and much of 2019 will see a continued accrual of favourable data around both PAT-DX1 and PAT-DX1-NP. The various pre-clinical studies will likely guide the choice of initial clinical indications for both PAT-DX1 and PAT-DX1-NP in the second half of this year, after which the product can go into toxicology studies ahead of the commencement of clinical work from late 2019
The original Hansen/Yale cell-penetrating patent US10040867 will expire om 4 March 2035. I would assume that we have a licence for this patent for the Patrys develpoments.
The BOT!!, page-70
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(14.3%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $3.862K | 1.287M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 36 | 30140120 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 22489307 | 15 |
View Market Depth
| Last trade - 12.55pm 10/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |